GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hypera SA (OTCPK:HYPMY) » Definitions » Net Change in Cash

HYPMY (Hypera) Net Change in Cash : $-236 Mil (TTM As of Mar. 2025)


View and export this data going back to . Start your Free Trial

What is Hypera Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Hypera's Net Change in Cash for the three months ended in Mar. 2025 was $0 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2025 was $-236 Mil.

Hypera Net Change in Cash Historical Data

The historical data trend for Hypera's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hypera Net Change in Cash Chart

Hypera Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only 485.33 -434.36 109.70 -57.47 -137.94

Hypera Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 119.19 -62.82 67.27 -240.83 0.14

Hypera Net Change in Cash Calculation

Hypera's Net Change in Cash for the fiscal year that ended in Dec. 2024 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=416.259+-97.105+-457.093+0
=-138

Hypera's Net Change in Cash for the quarter that ended in Mar. 2025

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=98.983+-33.251+-65.596+0
=0

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-236 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hypera Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Hypera's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Hypera Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hypera SA (OTCPK:HYPMY) » Definitions » Net Change in Cash
Comparable Companies
BSP:BLAU3 BSP:OFSA3 ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD NSE:DIVISLAB HKSE:03692 XSWX:SDZ XTAE:TEVA SHSE:688506 BOM:500087 TSE:4507 SZSE:000538 UTHR NSE:TORNTPHARM BOM:543904 BOM:500124
Traded in Other Exchanges
HM6A:Germany HYPE3:Brazil
Address
Avenida Magalhaes de Castro, 4800, 240 Floor Continental Tower Building, Bairro Cidade Jardim, Sao Paulo, SP, BRA, CEP 05676-120
Website
https://www.hypermarcas.com.br
Hypera SA is a specialty and generic drug manufacturing company. The company has a focus on the pharmaceutical segments of the Brazilian market, along with a presence in nonprescription drugs and branded generics. Hypermarcas also possesses a share of generic medicines and prescription products. The company also has a wide sales and distribution structure. The Company's operating segments are Consumer Health, Branded Prescription, Similars e Generics, Skincare and the Non-Retail Market.